Equities Analysts Offer Predictions for Ardelyx Q2 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at Wedbush lowered their Q2 2025 earnings estimates for shares of Ardelyx in a report issued on Tuesday, July 15th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter, down from their previous forecast of ($0.08). The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.32) EPS.

Other analysts have also recently issued reports about the stock. Raymond James Financial cut shares of Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 target price on the stock. in a research report on Friday, May 2nd. Wall Street Zen cut shares of Ardelyx from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. HC Wainwright began coverage on shares of Ardelyx in a research report on Wednesday, June 18th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Citigroup cut their price target on shares of Ardelyx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.89.

Ardelyx Stock Down 2.4%

Shares of NASDAQ ARDX opened at $4.41 on Thursday. The firm’s 50-day moving average price is $3.93 and its 200-day moving average price is $4.71. The company has a current ratio of 4.12, a quick ratio of 3.81 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -20.05 and a beta of 0.60. Ardelyx has a 12-month low of $3.21 and a 12-month high of $7.18.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The business had revenue of $74.11 million for the quarter, compared to analysts’ expectations of $79.40 million. Ardelyx had a negative net margin of 14.86% and a negative return on equity of 34.45%. The firm’s quarterly revenue was up 61.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.11) earnings per share.

Insider Activity at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 6,421 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $26,197.68. Following the transaction, the insider directly owned 402,583 shares in the company, valued at $1,642,538.64. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David M. Mott bought 381,377 shares of the company’s stock in a transaction on Friday, May 2nd. The stock was bought at an average price of $4.22 per share, for a total transaction of $1,609,410.94. Following the completion of the purchase, the director directly owned 2,396,871 shares in the company, valued at approximately $10,114,795.62. This represents a 18.92% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 881,377 shares of company stock worth $3,402,411 and sold 125,143 shares worth $517,667. 4.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC grew its stake in Ardelyx by 21.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 65,030 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 11,694 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Ardelyx by 79.6% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 233,248 shares of the biopharmaceutical company’s stock worth $914,000 after acquiring an additional 103,385 shares in the last quarter. Rhumbline Advisers grew its stake in Ardelyx by 4.1% in the 1st quarter. Rhumbline Advisers now owns 339,436 shares of the biopharmaceutical company’s stock worth $1,667,000 after acquiring an additional 13,312 shares in the last quarter. Strs Ohio bought a new position in shares of Ardelyx during the first quarter valued at approximately $135,000. Finally, Focus Partners Wealth bought a new position in shares of Ardelyx during the first quarter valued at approximately $72,000. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.